Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
February 12, 2025
A Revolution in Immunology: Creating New Possibilities with Oral Medicines
Arsalan Shabbir, MD, PhD, Vice President, Clinical Development
June 11, 2025
Powering Possibility Through Oral Medicines with Biologics-like Profiles
Nello Mainolfi, PhD, Founder, President and CEO
April 24, 2025
A New Era of Possibility: Addressing Coveted Undrugged Targets
Juliet Williams, PhD, Head of Research
Showing 41 news results
June 25, 2025
Boston Business Journal: Kymera signs $750M Gilead deal, announces $250M stock offering
June 25, 2025
FirstWord Pharma: Kymera snags Gilead as new partner, while Sanofi opts for next-gen IRAK4 degrader
June 5, 2025
Barron’s: Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
June 4, 2025
BiotechTV: Kymera Therapeutics’ Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company’s STAT6 healthy volunteer data
June 2, 2025
Biopharma Dive: Kymera, with new data, takes early step toward a Dupixent-like pill
June 2, 2025
Endpoints News: Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program
June 2, 2025
STAT News: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent
March 26, 2025
BiotechTV: State of Possible, Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company’s programs, including a new one to come
Our CEO, Nello Mainolfi, provides an overview of Kymera’s approach, pipeline, and upcoming milestones.
October 14, 2024
Nature Reviews Drug Discovery: Protein Degraders Push into Novel Target Space
Our CEO, Nello Mainolfi, was interviewed by Nature Reviews Drug Discovery to discuss how targeted protein degradation can unlock previously intractable disease targets, including our STAT6 and IRAK4 degraders in immunology.
Featured Presentations & Publications
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.